Abstract
The intracellular protein degradation system is critical for many cellular processes, including cell cycle regulation. The proteasomes are intracellular protein complexes that degrade polyubiquitinated proteins. Bortezomib (VelcadeĀ®) is a boronic acid dipeptide that directly binds to enzymatic complex to block chimotrypsin-like activity of proteasome and is the first FDA-approved proteasome inhibitor for multiple myeloma (MM) treatment. Bortezomib blocks degradation of multi-proteins, including regulators of cell cycle, anti-apoptosis, and inflammation, as well as immune surveillance. In MM cells, bortezomib directly induces cell stress response followed by activation of c-Jun NH2 terminal kinase/stress- activated protein kinase and triggers cell cycle arrest, followed by caspase-dependent apoptosis. Bortezomib also modulates activities of non-MM cellular components, including stromal cells and osteoblasts in the bone marrow milieu. Importantly, combination treatment strategies, including histone deacetylase inhibitors, Akt inhibitor, lenalidomide, heat shock protein 90 inhibitors, and aurora kinase inhibitors demonstrate significant anti-MM activities both in preclinical and clinical studies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Reference
Chauhan D, Catley L, Li G et al (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8:407ā419
Kuhn DJ, Chen Q, Voorhees PM et al (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110:3281ā3290
Kisselv AF, Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 21:1ā20
Hideshima T, Richardson PG, Anderson KC (2003) Targeting proteasome inhibition in hematologic malignancies. Rev Clin Exp Hematol 7:191ā204
Adams J (2004) The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4:349ā360
Hideshima T, Richardson P, Chauhan D et al (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071ā3076
Jost PJ, Ruland J (2007) Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 109:2700ā2707
Keats JJ, Fonseca R, Chesi M et al (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12:131ā144
Annunziata CM, Davis RE, Demchenko Y et al (2007) Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12:115ā130
Hideshima T, Chauhan D, Kiziltepe T et al (2009) Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood 113:5228ā5236
Baldwin AS Jr (1996) The NF-kB and I kB proteins: new discoveries and insights. Annu Rev Immunol 14:649ā683
Beg AA, Baldwin AS Jr (1993) The IkB proteins: multifunctional regulators of Rel NF-kB transcription factors. Genes Dev 7:2064ā2070
Zandi E, Chen Y, Karin M (1998) Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate. Science 281: 1360ā1363
DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M (1997) A cytokine-responsive IkB kinase that activates the transcription factor NF-kB. Nature 388:548ā554
Hideshima T, Ikeda H, Chauhan D et al (2009) Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 114:1046ā1052
Akiyama M, Hideshima T, Hayashi T et al (2002) Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 62:3876ā3882
Hideshima T, Mitsiades C, Akiyama M et al (2003) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101:1530ā1534
Hideshima T, Chauhan D, Schlossman RL, Richardson PR, Anderson KC (2001) Role of TNF-a in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 20:4519ā4527
Mitsiades N, Mitsiades CS, Richardson PG et al (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101:2377ā2380
Hideshima T, Chauhan D, Hayashi T et al (2003) Proteasome Inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22:8386ā8393
Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH (2003) Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA 100:9946ā9951
Gu H, Chen X, Gao G, Dong H (2008) Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells. Mol Cancer Ther 7:2298ā2307
LeBlanc R, Catley LP, Hideshima T et al (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62:4996ā5000
Klein B, Zhang XG, Lu XY, Bataille R (1995) Interleukin-6 in human multiple myeloma. Blood 85:863ā872
Hideshima T, Podar K, Chauhan D, Anderson KC (2005) Cytokines and signal transduction. Best Pract Res Clin Haematol 18:509ā524
Chauhan D, Uchiyama H, Akbarali Y et al (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kB. Blood 87:1104ā1112
Hideshima T, Chauhan D, Richardson P et al (2002) NF-kB as a therapeutic target in multiple myeloma. J Biol Chem 277:16639ā16647
Heider U, Kaiser M, Muller C et al (2006) Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 77:233ā238
Giuliani N, Morandi F, Tagliaferri S et al (2007) The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110: 334ā338
Mukherjee S, Raje N, Schoonmaker JA et al (2008) Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 118:491ā504
Qiang YW, Hu B, Chen Y et al (2009) Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 113:4319ā4330
von Metzler I, Krebbel H, Hecht M et al (2007) Bortezomib inhibits human osteoclastogenesis. Leukemia 21:2025ā2034
Vacca A, Ribatti D, Roncali L et al (1994) Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87:503ā508
Vacca A, Ribatti D, Presta M et al (1999) Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93:3064ā3073
Kumar S, Fonseca R, Dispenzieri A et al (2002) Bone marrow angiogenesis in multiple myeloma: effect of therapy. Br J Haematol 119:665ā671
Roccaro AM, Hideshima T, Raje N et al (2006) Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 66:184ā191
Mitsiades N, Mitsiades CS, Poulaki V et al (2002) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 99:14374ā14379
Tricot G, Barlogie B, Jagannath S et al (1995) Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250ā4256
Shaughnessy J, Tian E, Sawyer J et al (2000) High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 96:1505ā1511
Jagannath S, Richardson PG, Sonneveld P et al (2007) Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 21:151ā157
Chang H, Trieu Y, Qi X, Xu W, Stewart KA, Reece D (2007) Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res 31:779ā782
Mitsiades N, Mitsiades CS, Richardson PG et al (2003) Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101:4055ā4062
Hideshima T, Bradner JE, Chauhan D, Anderson KC (2005) Intracellular protein degradation and its therapeutic implications. Clin Cancer Res 11:8530ā8533
Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115:727ā738
Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL (2003) Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 100:4389ā4394
Hideshima H, Bradner JE, Wong J et al (2005) Small molecule inhibition of proteasome and aggresome function induces synergistic anti-tumor activity in multiple myeloma. Proc Natl Acad Sci USA 102:8567ā8572
Catley L, Weisberg E, Kiziltepe T et al (2006) Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 108:3441ā3449
Mitsiades CS, Mitsiades NS, McMullan CJ et al (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101:540ā545
Pei XY, Dai Y, Grant S (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10:3839ā3852
Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S (2007) The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol 139:385ā397
Deleu S, Lemaire M, Arts J et al (2009) Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Res 69:5307ā5311
Hideshima T, Catley L, Yasui H et al (2006) Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107:4053ā4062
Hideshima T, Nakamura N, Chauhan D, Anderson KC (2001) Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 20:5991ā6000
Hideshima T, Catley L, Raje N et al (2007) Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 138:783ā791
Ogata A, Chauhan D, Urashima M, Teoh G, Treon SP, Anderson KC (1997) Blockade of mitogen-activated protein kinase cascade signaling in interleukin-6 independent multiple myeloma cells. Clin Cancer Res 3:1017ā1022
Mitsiades CS, Mitsiades N, Poulaki V, Akiyama M, Treon SP, Anderson KC (2001) The HSP90 molecular chaperone as a novel therapeutic target in hematologic malignancies. Blood 98:377a
Mitsiades CS, Mitsiades NS, McMullan CJ et al (2006) Antimyeloma activity of heat shock protein-90 inhibition. Blood 107:1092ā1100
Stuhmer T, Zollinger A, Siegmund D et al (2008) Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia 22:1604ā1612
Okawa Y, Hideshima T, Steed P et al (2009) SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematological tumors by abrogating signaling via Akt and ERK. Blood 113(4):846ā855
Mimnaugh EG, Xu W, Vos M et al (2004) Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 3:551ā566
Davenport EL, Moore HE, Dunlop AS et al (2007) Heat shock protein inhibition is associated with activation of the unfolded protein response (UPR) pathway in myeloma plasma cells. Blood 110(7):2641ā2649
Hideshima T, Chauhan D, Shima Y et al (2000) Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943ā2950
Davies FE, Raje N, Hideshima T et al (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210ā216
Mitsiades N, Mitsiades CS, Poulaki V et al (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99:4525ā4530
Hayashi T, Hideshima T, Akiyama M et al (2005) Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 128: 192ā203
Richardson PG, Schlossman RL, Weller E et al (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063ā3067
Richardson PG, Blood E, Mitsiades CS et al (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108:3458ā3464
Richardson P, Jagannath S, Hussein M et al (2009) Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 114:772ā778
Dimopoulos M, Spencer A, Attal M et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123ā2132
Weber DM, Chen C, Niesvizky R et al (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133ā2142
Richardson P, Jagannath S, Jakubowiak A et al (2008) Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phase II study. Blood 112:614
Richardson P, Jagannath S, Jakubowiak A et al (2008) Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study. Blood 112:41
Shi Y, Reiman T, Li W et al (2007) Targeting aurora kinases as therapy in multiple myeloma. Blood 109:3915ā3921
Chng WJ, Braggio E, Mulligan G et al (2008) The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood 111:1603ā1609
Hose D, Reme T, Meissner T et al (2009) Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 113:4331ā4340
Dutta-Simmons J, Zhang Y, Gorgun G et al (2009) Aurora kinase A is a target of Wnt/{beta}-catenin involved in multiple myeloma disease progression. Blood 114(3):2699ā2708
Yu C, Rahmani M, Dent P, Grant S (2004) The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor bortezomib. Exp Cell Res 295:555ā566
Zou W, Yue P, Lin N et al (2006) Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res 12:273ā280
Perrone G, Hideshima T, Ikeda H et al (2009) Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 23(9):1679ā1686
Golden EB, Lam PY, Kardosh A et al (2009) Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 113: 5927ā5937
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2011 Springer Basel AG
About this chapter
Cite this chapter
Hideshima, T., Richardson, P.G., Anderson, K.C. (2011). Preclinical Activities of Bortezomib in MM, the Bone Marrow Microenvironment and Pharmacogenomics. In: Ghobrial, I., Richardson, P., Anderson, K. (eds) Bortezomib in the Treatment of Multiple Myeloma. Milestones in Drug Therapy. Springer, Basel. https://doi.org/10.1007/978-3-7643-8948-2_2
Download citation
DOI: https://doi.org/10.1007/978-3-7643-8948-2_2
Published:
Publisher Name: Springer, Basel
Print ISBN: 978-3-7643-8947-5
Online ISBN: 978-3-7643-8948-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)